Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cost-effectiveness of treatment for chronic hepatitis C infection

Newer treatment options for hepatitis C are reasonably cost-effective, but results vary widely across patient subgroups and depend on quality-of-life assumptions, find researchers in this week's issue of the Journal of the American Medical Association.

News image

fiogf49gjkf04

Over 2.5 million people in the United States have chronic hepatitis C virus (HCV) infection.

However, as public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage.

In this study, researchers examined the benefits and cost-effectiveness of treatments for chronic hepatitis C infection in asymptomatic, HCV sero-positive, but otherwise healthy individuals.

The team performed a cost-effectiveness analysis using a Markov model of the natural history of HCV infection and impact of treatment.

Probability of developing cirrhosis over a 30-year period was between 13% and 46% for men, and 1% and 29% for women.
Journal of the American Medical Association

They derived natural history parameters from an epidemiologic model. These were empirically calibrated to provide a good fit to observed data on both prevalence of HCV seropositivity and time trends in outcomes.

The researchers assessed cohorts of 40-year-olds who had elevated levels of alanine aminotransferase, positive HCV RNA assays and serologic tests for antibody to HCV. Subjects had no histological evidence of fibrosis on liver biopsy.

The subjects were treated using either standard or pegylated interferon alfa-2b, or combination therapy with standard or pegylated interferon plus ribavirin.

The team evaluated the lifetime costs of treatment, life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.

The researchers found that the probability of patients with chronic HCV developing cirrhosis over a 30-year period was between 13% and 46% for men, and 1% and 29% for women.

They determined that the incremental cost-effectiveness of combination therapy with pegylated interferon for men was between $26,000 and $64,000 per QALY for genotype 1, and between $10,000 and $28,000 for other genotypes.

The cost-effectiveness for women was between $32,000 and $90,000 for genotype 1, and between $12,000 and $42,000 for other genotypes.

The research team found that the benefits of treatment were largely improvements in health-related quality of life, rather than prolonged survivorship, meaning that cost-effectiveness ratios expressed as dollars per year of life were substantially higher.

In addition, results were most sensitive to assumptions about the gains and decrements in health-related quality of life associated with treatment.

Dr Joshua Salomon's team concluded, "While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions".

"As the pool of persons eligible for treatment for HCV infection expands to the more general population, it will be imperative for patients and their physicians to consider these assumptions in making individual-level treatment decisions".

JAMA 2003; 290(2): 228-37
10 July 2003

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us